Servier ends clinical trials for sevasemten in both Becker and Duchenne muscular dystrophy

After the recent and disappointing news that the GRAND CANYON study in Becker muscular dystrophy did not meet its primary or key secondary endpoints, and a Governance Committee review of all the Becker and Duchenne data, Servier has decided to stop the studies in both diseases.

This is deeply disappointing news, and certainly not the outcome we had hoped for.  We want to thank individuals and families who have participated in these studies, as well as the Edgewise and Servier teams, for their valuable contributions to our community. 

Please see community letter below.